A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the change in Hepatitis C Virus RNA during
dosing with daclatasvir and during the follow-up period in subjects with chronic hepatitis C
infection